Introduction
RKTG (Raf Kinase Trapping to Golgi), a member of the PAQR (Progestin and AdipoQ Receptors) family, is a seven-transmembrane protein specifically located at the Golgi apparatus in mammalian cells (Feng et al., 2007; Luo et al., 2008) . Our previous studies have revealed that RKTG acts as a spatial regulator of Raf kinase by sequestering Raf to the Golgi apparatus, thereby antagonizing the mitogen-activated protein kinase (Raf/MEK/ERK) signaling cascade (Feng et al., 2007; Fan et al., 2008) . RKTG functions as a tumor suppressor because of its inhibitory activity on Raf/MEK/ERK signaling. When overexpressed in A375 melanoma cells that bear a B-Raf (V600E) mutation, RKTG is able to reduce cell viability and colony formation in vitro, and inhibits tumor growth in a xenograft assay in vivo (Fan et al., 2008) . Deletion of RKTG in the mouse leads to increased incidence of skin tumorigenesis upon induction by chemical mutagens DMBA (7,12-dimethylbenz[a] anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetate) (Xie et al., 2008) .
Vascular endothelial growth factors (VEGFs) have a central role in angiogenesis, vasculogenesis and lymphangiogenesis (Ferrara, 2004; Lohela et al., 2009) . The VEGF family of growth factors is composed of five members in mammals and they interact with three transmembrane tyrosine kinase receptors. For angiogenesis of blood vessel endothelial cells, VEGF signaling via VEGFR-2 is the most important pathway that executes angiogenesis program by inducing proliferation, survival, migration, sprouting and maintenance of cell permeability of endothelial cells (Lohela et al., 2009) . Binding of VEGF with VEGFR-2 leads to receptor dimerization and autophosphorylation at many tyrosine kinase residues (Dougher and Terman, 1999; Matsumoto and Mugishima, 2006) , in which phosphorylation of tyrosine at 1175 (or 1173 in mouse) activates the phospholipase Cg/protein kinase C pathway, leading to the activation of Raf/MEK/ERK signaling cascade (Matsumoto and Mugishima, 2006) .
Recent studies on clear-cell renal cell carcinoma (ccRCC) have provided an excellent example that links von Hippel-Lindau (VHL)-and hypoxia-inducible factor 1a (HIF-1a)-mediated hypoxia response to angiogenesis in a tumor. About 75% of kidney cancer cases are classified as ccRCC, a highly vascularized tumor. VHL, a product of VHL tumor suppressor crucial for degradation of HIF-1a (Maxwell et al., 1999) , is found to be inactivated in most hereditary and sporadic ccRCCs, highlighting the central role of VHL and angiogenesis in the tumorigenesis of ccRCC (Iliopoulos et al., 1995) . However, how other genetic alterations are involved in the carcinogenesis of ccRCC is largely unknown. For example, deletion of VHL in the mouse could dysregulate HIF, but not promote cancer growth (Mack et al., 2003) , suggesting that other factors are likely required for the tumorigenesis of ccRCC.
In this study, we analyzed the regulatory function of RKTG, a spatial regulator of Raf kinase, in VEGFmediated signaling and angiogenesis. We demonstrate that RKTG is actively implicated in regulating many facets of VEGF-mediated activities, such as cell proliferation, migration, sprouting and angiogenesis in endothelial cells. We also found that RKTG negatively regulates VEGF expression by reducing the transactivation activity of HIF-1a, thus blocking the autocrine VEGF signaling. Furthermore, the expression level of RKTG is significantly downregulated in clinical ccRCC samples, which is correlated with an upregulation of VEGF. These results, therefore, uncover a new role of RKTG in the regulation of angiogenesis and ccRCC tumorigenesis.
Results

RKTG inhibits VEGF-stimulated ERK phosphorylation and cell proliferation in endothelial cells
The Raf/MEK/ERK signaling pathway has been implicated in intracellular signaling of VEGF (Ferrara, 2004; Lohela et al., 2009) . As RKTG is able to modulate Raf/MEK/ERK cascade by sequestrating Raf kinase to the Golgi apparatus (Feng et al., 2007; Fan et al., 2008) , we hypothesized that RKTG might have a role in VEGF-mediated biological activities. We first analyzed whether or not RKTG is able to regulate VEGFinduced ERK phosphorylation in human umbilical vein endothelial cells (HUVECs). Treatment of HUVECs with VEGF could rapidly stimulate ERK phosphorylation ( Figure 1a ). Overexpression of a Myc-tagged RKTG significantly abrogated VEGF-induced ERK phosphorylation ( Figure 1a) . Treatment of HUVECs with VEGF could significantly elevate the cell proliferation rate and such effect was completely abolished when RKTG was overexpressed (Figure 1b) . We constructed lentivirus that expressed small hairpin RNA (shRNA) specific for RKTG. Two RKTG shRNAs were analyzed and both of them could silence expression of RKTG at the mRNA level, although one of them (#2) had a much better efficiency to knock down RKTG expression (Supplementary Figure 1) . All the subsequent shRNArelated experiments were performed with the #2 shRNA. When the endogenous RKTG was silenced by RKTG shRNA, both the basal and VEGF-stimulated cell proliferation rate in HUVECs were significantly increased ( Figure 1c ). Taken together, these results suggest that RKTG can modulate VEGF-mediated ERK signaling and cell proliferation in endothelial cells.
RKTG negatively regulates migration and tube formation of endothelial cells
As cell migration is a pivotal step for angiogenesis, we next examined the effect of RKTG on VEGF-induced HUVEC migration in a transwell assay. HUVECs infected with either control lentivirus or RKTG-expressing lentivirus were seeded into the transwell and the cell migration rate was monitored with or without VEGF treatment. As expected, VEGF treatment could significantly elevate cell migration (Figure 2a) . However, overexpression of RKTG not only reduced cell migration at basal state but also inhibited VEGF-induced cell migration (Figure 2a) . Consistently, knockdown of endogenous RKTG by shRNA-containing lentivirus could increase cell migration in the absence of VEGF treatment, and also profoundly potentiate VEGFstimulated migration of HUVECs (Figure 2b) . We also applied a wound-healing experiment to further investigate the effect of RKTG on endothelial cell migration. The same number of HUVECs infected with either control lentivirus or the virus containing RKTG shRNA were plated. Knockdown of endogenous RKTG in HUVECs significantly accelerated wound healing in the absence or presence of VEGF (Figure 2c) .
We also performed a tube formation assay with HUVECs. The cells were infected with either control lentivirus or RKTG shRNA lentivirus and loaded onto Matrigel in the presence of VEGF. After 8 h of incubation, although control cells showed very few cellcell connection, HUVECs infected with RKTG shRNA formed numerous tube-like structures accompanied by the appearance of 'nodes' (Figure 2d ), providing in vitro evidence that RKTG is implicated in the regulation of angiogenesis. Furthermore, the enhanced tube formation by RKTG knockdown could be completely blocked by an MEK inhibitor, PD98059, indicating that the modulatory function of endogenous RKTG on angiogenesis is mediated by the Raf/MEK/ERK pathway.
Deletion of RKTG enhances VEGF-mediated angiogenesis Next, we analyzed the inhibitory effect of RKTG on angiogenesis using RKTG knockout mice (Feng et al., 2007; Xie et al., 2008) . Primary mouse embryonic fibroblasts (MEFs) were isolated from wild-type or RKTG À/À mice. Both VEGF and epidermal growth factor treatments were able to induce ERK phosphorylation, which was markedly enhanced when RKTG was deleted (Figure 3a) . We analyzed blood vessel sprouting using an aortic ring assay. Aortic rings from both the wild-type and RKTG-deleted littermates were isolated and embedded in VEGF-containing Matrigel for 7 days, followed by measurement of sprouting (Haas et al., 2006) . Endothelial cells from the aortic rings of wildtype mice did not have significant outgrowth, whereas the sprouting of the rings from RKTG-deleted mice was dramatically increased (Figure 3b) . The in vivo function of RKTG on angiogenesis was further investigated by a Matrigel plug assay. The same amount of Matrigel was injected subcutaneously in the mid-ventral abdominal region of mice together with VEGF. The Matrigel plugs were excised and used for immunohistochemistry with an anti-CD31 (PECAM-1) antibody to stain endothelial cells. Interestingly, the number of invaded endothelial cells in the Matrigel plug embedded in RKTG-deleted mice was significantly increased (Figure 3c ). Most CD31-positive cells from the wild-type mice were dispersed in the plug without obvious structure. However, in RKTG-deleted mice, many of the CD31-positive cells were arranged in a trabeculated structure ( Figure 3c , marked by arrows), indicating the formation of capillary-like structures. Collectively, these findings suggest that deletion of RKTG can enhance VEGFinduced angiogenesis in vivo.
RKTG inhibits HIF-1a-and hypoxia-stimulated VEGF transcription and expression
To investigate the potential molecular mechanism underlying the regulation of RKTG on angiogenesis, we analyzed whether RKTG could affect VEGF expression. HIF-1a is the primary transcription factor that imparts hypoxia signal to VEGF regulation through the HIF-responsive element within the promoter region of VEGF gene (Levy et al., 1995; Liu et al., 1995) . We examined the effect of RKTG on HIF-1a-mediated stimulation on the VEGF promoter. In HEK293T cells, expression of HIF-1a could markedly increase the activity of VEGF promoter ( Figure 4a ). However, overexpression of RKTG significantly attenuated the stimulatory effect of HIF-1a on VEGF promoter ( Figure 4a ). Furthermore, knockdown of RKTG by shRNA could enhance HIF-1a-stimulated transcriptional activity of VEGF promoter ( Figure 4b) . Interestingly, such effect was abrogated in the presence of MEK inhibitor PD98059 (Figure 4b ).
To further confirm these results, we analyzed whether RKTG also had an effect on hypoxia-induced VEGF gene expression (Figure 4c ). In HEK293T cells, hypoxia could profoundly elevate VEGF promoter activity, similar to the observation with overexpressed HIF-1a. Knockdown of RKTG by shRNA potentiated the stimulatory activity of hypoxia on VEGF promoter, and such effect was abrogated by co-expression of an shRNA-resistant RKTG plasmid (Supplementary Figure 2) . PD98059 treatment could also abrogate the stimulation of VEGF transcription by hypoxia. Furthermore, the enhancement of RKTG shRNA on hypoxiainduced VEGF promoter activity was inhibited by PD98059. The potentiation of RKTG shRNA on hypoxia-induced VEGF promoter activity was also partially abrogated when an shRNA-resistant RKTG was co-expressed, further indicating the RKTG shRNA is specific in silencing RKTG expression. Taken together, these data indicate that RKTG can inhibit HIF-1a-and hypoxia-stimulated VEGF expression and such inhibition is mediated by the Raf/MEK/ERK signaling pathway.
We next analyzed whether RKTG could regulate the mRNA level of VEGF. Two major isoforms (165aa and 121aa) of VEGF were analyzed by reverse transcriptase-PCR (RT-PCR) in HUVECs under hypoxia condition and RKTG shRNA could apparently elevate both isoforms of VEGF (Supplementary Figure 3) . We also examined the VEGF expression level in MEFs isolated from wild-type or RKTG-deleted mice. Under hypoxia condition, the VEGF mRNA level detected by real-time RT-PCR was significantly higher in RKTG-deleted MEFs than in the wild-type cells (Figure 4d ). Correspondingly, the VEGF protein level secreted by MEFs was also elevated by RKTG deletion (Figure 4e ). Collectively, these data indicate that RKTG negatively regulates VEGF expression at both the mRNA and protein levels under hypoxia condition.
RKTG affects the transactivation activity of HIF-1a and HIF-1a/p300 interaction We investigated whether RKTG could change the protein level of HIF-1a and found that RKTG had no effect on the stability of HIF-1a (Supplementary Figure  4) . Meanwhile, RKTG could not affect the interaction of HIF-1a with HIF-1b (Supplementary Figure 5) . In addition, RKTG had no effect on the hypoxia-induced HIF protein complex that binds to an HIF-responsive element (Supplementary Figure 6) . We therefore speculated that RKTG might affect the transactivation activity of HIF-1a to regulate VEGF expression. The transactivation activity of HIF-1a was analyzed by a Gal4-luciferase system (Hur et al., 2001) , in which the Cterminal transactivation domain (787-826aa) of human HIF-1a was cloned into the Gal4 vector (Gal4-CAD). The CAD domain of HIF-1a interacts with a general transcription co-activator p300/CBP to mediate transactivation activity of HIF-1a (Arany et al., 1996; Kallio et al., 1998) . As a negative control, the Gal4-luciferase reporter itself, with or without co-expression of RKTG, had no transcriptional activity (Figure 5a ). Gal4-CAD could stimulate the activity of the Gal4-luciferase reporter (Figure 5a) . Interestingly, co-expression of RKTG significantly decreased the Gal4-CAD-stimulated luciferase activity (Figure 5a ), providing evidence that RKTG is implicated in the regulation of transactivation activity of HIF-1a.
We next investigated whether endogenous RKTG could regulate the transactivation of HIF-1a through RNA interference strategy ( Figure 5b ). As expected, hypoxia was able to elevate the transactivation activity of HIF-1a. Knockdown of RKTG could significantly upregulate the trans-activity of HIF-1a under both normoxia and hypoxia conditions. An shRNA-resistant RKTG could partially abrogate the enhancement of RKTG shRNA on HIF-1a trans-activity. PD98059 markedly reduced either the basal or RKTG shRNAenhanced HIF-1a transactivation activity, indicating that the regulatory function of RKTG on HIF-1a transactivity is mediated by the Raf/MEK/ERK signaling pathway.
It was previously reported that the transactivation activity of HIF-1a is dependent on the recruitment of its co-activator p300 (Sang et al., 2003) . We examined whether RKTG could affect this process by analyzing the physical interaction between p300 and HIF-1a-CAD (Ema et al., 1999) . The cell lysate was incubated with the same amount of purified glutathione S-transferase (GST) or GST-HIF-1a-CAD (530-826aa), and the GST pull-down product was used in immunoblotting ( Figure 5c ). Only GST-HIF-1a-CAD but not GST was able to pull down p300. However, co-expression of RKTG or treatment with PD98059 abrogated the pull-down of p300 by GST-HIF-1a-CAD (Figure 5c ). The transactivation activity of HIF-1a is inhibited by RKTG overexpression. HEK293T cells were transfected with the Gal4 reporter plasmid alone, or together with pGal4-HIF-1a-CAD (Gal4-CAD) as indicated, followed by luciferase assay. The fold change of luciferase activity is shown as mean±s.d. **Po0.01. (b) The transactivation activity of HIF-1a is enhanced by RKTG knockdown. HEK293T cells were transfected with the plasmids as indicated together with Gal4-CAD luciferase reporter, with or without PD98059 treatment. Luciferase assay was performed to determine the trans-activity of HIF-1a. The fold change of luciferase activity is shown as mean ± s.d. *Po0.05 and **Po0.01 between normoxia and hypoxia treatments in each group. (c) In vitro interaction of HIF-1a with p300 is inhibited by RKTG by GST pull-down assay. Same amounts of GST or GST-HIF-1a (530-826aa) were incubated with whole-cell lysate isolated from HEK293T cells transfected with RKTG or treated with PD98059 as indicated, followed by GST pull-down and immunoblotting. The top panel shows the result of immunoblotting with an anti-p300 antibody with the pull-down product. The bottom panel shows the expression of proteins in the input. (d) In vivo interaction of HIF-1a with p300 is enhanced by RKTG knockdown. HUVECs infected with either control or RKTG shRNA lentivirus were treated with PD98059 (50 mM) for 1 h as indicated, or exposed to hypoxia for 6 h as indicated. The cell lysate was used in a co-immunoprecipitation assay to determine the interaction of HIF-1a with p300.
We next investigated whether RKTG could affect endogenous HIF-1a/p300 interaction by a co-immunoprecipitation assay (Figure 5d ). We found that hypoxia was able to elevate the interaction of HIF-1a with p300, and such interaction was markedly enhanced when RKTG was silenced. Furthermore, treatment of the cells with PD98059 abrogated the enhancement of interaction of HIF-1a with p300. Taken together, these data indicate that RKTG is implicated in the regulation of the interaction of HIF-1a with p300 in a mitogenactivated protein kinase-dependent manner.
RKTG is downregulated in ccRCC, with an inverse correlation with VEGF expression level As our previous studies indicate that RKTG is a putative tumor suppressor gene (Fan et al., 2008; Xie et al., 2008 ), we analyzed the expression level of RKTG in multiple human tumors by tissue array. Among the common types of human tumors, such as those of the lung, liver, colon, pancreas, breast and kidney, we found that RKTG was mainly altered in renal cancer. We further analyzed 31 pairs of ccRCC tumor samples with adjacent normal tissue controls by immunohistochemistry with a polyclonal anti-RKTG antibody (Feng et al., 2007) . In comparison with the adjacent tissue controls, three ccRCC samples (B10%) had an equivalent expression level. However, 28 ccRCC samples (B90%) had an apparently lower expression level of RKTG than the control samples (Figures 6a and b) .
To further confirm these results, we carried out realtime RT-PCR to evaluate the mRNA levels of RKTG in 48 pairs of clinical ccRCC samples and the matched adjacent tissue controls. The mRNA level of b-actin in each sample was quantified as an internal standard to normalize the relative level of RKTG in the same sample. In 66.7% (32/48) of the tumors, RKTG mRNA level was lower than the controls, whereas 58.3% (28/48) of the tumors had an RKTG expression level that was decreased greater than twofold than the controls. Meanwhile, 14.6% (7/48) of the ccRCCs had no significant change of RKTG mRNA level and 27.1% (13/48) of tumors had an increased level of RKTG mRNA. In summary, the mRNA level of RKTG was significantly reduced in ccRCC tumor samples (P ¼ 0.0119).
As our previous experiments indicate that RKTG negatively regulates VEGF signaling and hypoxiainduced VEGF production, we hypothesized that the reduced RKTG level in ccRCC samples should be associated with an elevated level of VEGF expression. To test this hypothesis, we analyzed the VEGF mRNA expression level in the 48 pairs of clinical ccRCC samples and 37 pairs with detectable expression were show in Figure 3c . Compared with the adjacent tissue controls, 67.6% (25/37) of the tumors had an increased VEGF mRNA level greater than twofold than the controls. The expression level of VEGF mRNA was significantly increased in the ccRCC samples (P ¼ 0.0014). Furthermore, we compared both the VEGF and RKTG mRNA levels in those samples and a significant inverse correlation was observed between the mRNA levels of these two genes (r 2 ¼ À0.34, P ¼ 0.039). These results, therefore, highly suggest that RKTG is significantly reduced in ccRCC, accompanied by an increase of VEGF.
Discussion
In this study, we reveal for the first time that RKTG has an important role in the regulation of angiogenesis and downregulation of RKTG is associated with ccRCC, a highly vascularized human tumor. In summary, we made the following observations:
(1) RKTG has an inhibitory function on VEGF signaling in endothelial cells. Overexpression of RKTG inhibits VEGF-induced ERK phosphorylation in HUVECs. The VEGF-stimulated cell proliferation is reduced by RKTG overexpression and elevated by RKTG knockdown in HUVECs.
(2) RKTG has an inhibitory role in VEGF-mediated angiogenesis in endothelial cells. In addition, knockdown of RKTG increases VEGF-induced migration and tube formation in HUVECs. Deletion of RKTG in the mouse promotes VEGF-mediated sprouting and new blood vessel formation.
(3) RKTG inhibits VEGF expression. HIF-1a-induced VEGF promoter activity is reduced by RKTG overexpression. Both HIF-1a-and hypoxia-stimulated VEGF promoter activities are enhanced by RKTG knockdown. Furthermore, RKTG deletion in MEFs is associated with enhanced ERK phosphorylation and increased expression of VEGF at both the mRNA and protein levels under hypoxia condition.
(4) RKTG inhibits the hypoxia-induced transactivation activity, but not protein stability, of HIF-1a. In addition, the interaction of HIF-1a with p300 is inhibited by RKTG overexpression and enhanced by RKTG silencing.
(5) RKTG is downregulated in clinical ccRCC tumor samples. Both the protein and mRNA levels of RKTG are significantly reduced in ccRCC tumors in comparison with the adjacent tissue controls.
Furthermore, downregulation of RKTG in ccRCC is inversely correlated with an elevated level of VEGF. Taken together, these data pinpoint that RKTG is actively implicated in the regulation of VEGF-induced angiogenesis and HIF-1a-mediated VEGF autocrine function.
Our study further highlights the importance of Raf/ MEK/ERK signaling cascade in angiogenesis. Throughout the experiments we found that the regulatory function of RKTG in angiogenesis is dependent on the Raf/MEK/ERK signaling cascade that is negatively modulated by RKTG (Feng et al., 2007; Fan et al., 2008) . Consistently, knockdown or deletion of RKTG is able to enhance VEGF-induced ERK phosphorylation. The enhancement of RKTG shRNA on VEGF-induced migration and tube formation in HUVECs is abrogated by MEK inhibitor PD98059. The increase in HIF-1a-and hypoxia-induced VEGF promoter activity by RKTG knockdown is also abrogated by PD98059.
Furthermore, the elevated transactivation activity of HIF-1a and HIF-1a/p300 interaction by RKTG shRNA is abrogated by PD98059. All these data, collectively, indicate that the Raf/MEK/ERK signaling pathway is indispensable for the regulation of RKTG in VEGF-and hypoxia-mediated angiogenesis. Upon VEGF binding, VEGFR2 undergoes dimerization and autophosphorylation at many tyrosine kinase residues (Dougher and Terman, 1999; Matsumoto et al., 2005) , in which tyrosine phosphorylation at 1175 (or 1173 in mouse) activates the phospholipase Cg/protein kinase C pathway, leading to activation of the Raf/MEK/ERK signaling cascade (Guo et al., 1995; Xia et al., 1996; Matsumoto and Mugishima, 2006) . The importance of the Raf/MEK/ERK signaling pathway in VEGFmediated angiogenesis is also supported by the finding that Raf-1 has a pivotal role in protecting endothelial cells from extrinsic-mediated apoptosis during angiogenesis (Alavi et al., 2003) . In addition, our data are consistent with the finding that PD98059 is able to block the proliferation, migration and tube formation of endothelial cells in vitro (Wu et al., 2000; Srivastava et al., 2009) . Intriguingly, the regulatory function of RKTG in angiogenesis is similar to that of Spred-1, which also functions as a negative regulator of Raf kinase by interfering with the phosphorylation and activation of Raf-1 (Wakioka et al., 2001) . A study with micro-RNA miR-126 that targets Spred-1 has led to the discovery that miR-126 enhances angiogenesis by activation of ERK signaling . In this study, we demonstrate that the RKTGregulated Raf/MEK/ERK signaling pathway is pivotal for the transactivation activity of HIF-1a to induce VEGF expression. Previous studies have indicated that HIF-1a is a substrate of phosphorylated ERK and that the phosphorylation of HIF-1a at Ser641 and Ser643 is required for its nuclear location and trans-activity (Mylonis et al., 2006) . On the other hand, the recruitment of p300/CBP into the HIF-1 transcriptional complex is indispensable for the transactivation activity of HIF-1 (Arany et al., 1996) . It was previously found that PD98059 is able to disrupt the interaction of HIF-1a with p300/CBP and inhibits the downstream signaling of HIF-1a (Sang et al., 2003) . In this study, we found that the enhancement of RKTG silencing on hypoxia-induced VEGF promoter activity and HIF-1a/ p300 interaction is abrogated by PD98059. These observations, therefore, have consolidated that the Raf/ MEK/ERK signaling cascade is crucial for the transactivation activity of HIF-1a.
On the basis of our study, we propose that the Raf/ MEK/ERK signaling cascade, which is negatively regulated by RKTG, is implicated in an autocrine loop to propagate VEGF action and maintain homeostasis of angiogenesis (Figure 6d ). In this model, VEGF's binding with the VEGF receptor, mainly VEGFR2 in endothelial cells, leads to the activation of Raf/MEK/ERK signaling and other signaling events to initiate the angiogenic program. Although the Raf/MEK/ERK signaling cascade itself imparts the signal of VEGF to cell proliferation and antiapoptosis, it activates the transactivation activity of HIF-1a, leading to an increase in VEGF gene expression. The increased VEGF then acts on the same cell in an autocrine manner to further enhance VEGF action. Upregulation of the Raf/ MEK/ERK pathway, such as RKTG downregulation, would accelerate Raf/MEK/ERK-mediated VEGF autocrine function. This model of autocrine VEGF signaling is supported by earlier observations. One study has revealed that H-Ras-and v-Raf-transformed NIH3T3 cells could produce more VEGF with the stimulation of platelet-derived growth factor or TPA (Grugel et al., 1995) . A dominant-negative Raf-1 could inhibit VEGF expression in 293 cells (Mukhopadhyay et al., 1995) . In addition, deletion of HIF-1a specifically in endothelial cells can also disrupt the VEGF autocrine loop, implicated in angiogenesis of solid tumors (Tang et al., 2004) . Furthermore, a recent study using specific deletion of VEGF in endothelial cells has demonstrated that endothelial integrity and survival depends on the maintenance of low-level autocrine VEGF signaling, which is pivotal for maintaining vascular homeostasis (Lee et al., 2007) . Therefore, it can be postulated that the crucial function of autocrine VEGF signaling in vascular homeostasis is mediated by the Raf/MEK/ ERK signaling cascade and negatively regulated by endogenous RKTG in endothelial cells.
With the above hypothesis in mind, it can be envisioned that disruption of the autocrine VEGF signaling through dysregulation of Raf/MEK/ERK signaling cascade would lead to abnormal angiogenesis in pathological scenarios.
Interestingly, we found that RKTG is significantly downregulated in sporadic ccRCC tumor samples. Furthermore, the downregulation of RKTG is inversely correlated with an upregulation of VEGF in the tumors. The ccRCC is a highly vascularized tumor with the characteristics of pathologically enhanced angiogenesis. The accelerated angiogenic feature of ccRCC is best exemplified by the finding that VHL is defective in most inherited and sporadic ccRCCs. VHL is actively involved in the regulation of angiogenesis by affecting the protein stability of HIF-1a (Iwai et al., 1999; Lisztwan et al., 1999) . Defective VHL, as commonly seen in ccRCC, causes an increase in HIF-1a protein level, which in turn activates transcription of VEGF and other hypoxiaresponsive genes, leading to increased angiogenesis. Understanding the dysregulated angiogenic network underlying the pathogenesis of ccRCC has paved the way for the development of targeted drugs for treatment of cancers, especially ccRCC. Recently, a series of angiogenesis-targeted drugs such as bevacizumab, sunitinib and sorafenib have been successfully developed with promising clinical outcomes, especially in ccRCC (Ferrara, 2004; Escudier et al., 2007; Motzer et al., 2007) . Our finding that RKTG is significantly downregulated in ccRCC indicates that, in addition to loss of VHL, an upregulation of the Raf/MEK/ERK signaling, owing to the reduction of RKTG, is likely important for the carcinogenesis of ccRCC. On the one hand, downregulation of RKTG can be considered as a new in vivo molecular marker of ccRCC. On the other hand, an enhanced Raf/MEK/ERK signaling cascade, owing to the downregulation of RKTG, may potentiate the autocrine VEGF signaling and synergize with loss of VHL to increase HIF-1a protein level, thereby promoting the highly vascularized features of ccRCC. The idea that dysregulation of both VHL and Raf/MEK/ERK pathways is needed for the carcinogenesis of ccRCC is further supported by the discovery that sorafenib is highly effective in the treatment of ccRCC and other cancers (Escudier et al., 2007; Llovet et al., 2008) . Sorafenib was originally developed as an inhibitor of Raf-1 kinase. It was later found that sorafenib can inhibit multiple tyrosine kinases, such as the VEGF receptor (Wilhelm et al., 2006) . Interestingly, RKTG is an in vivo inhibitor of Raf kinase. Therefore, discovery of the regulatory function of RKTG in angiogenesis as well as its downregulation in ccRCC would not only highlight the importance of the Raf/MEK/ERK pathway in autocrine VEGF signaling, but also greatly aid in understanding the molecular pathogenesis of ccRCC, a tumor closely associated with angiogenesis.
Materials and methods
A full description of the materials and methods is included in the Supplementary Information.
Cell proliferation, migration and tube formation assays of HUVEC MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay to analyze HUVECs proliferation was performed as described previously (Xie et al., 2008) . The transwell migration assay was carried out as described previously (Yi et al., 2008) . Briefly, HUVECs were seeded onto transwell first, and after the cells were attached, the medium in the bottom chambers was changed to Dulbecco's modified Eagle's medium with or without VEGF. The cells that migrated onto the bottom surface were fixed and measured. The wound-healing migration assay was performed with HUVECs after lentivirus infection, with the wound produced by scratching with the pipette tip. For Matrigel experiments, HUVECs were seeded in Matrigel and tube formation was photographed at 8-48 h after the incubation.
Aortic ring assay and Matrigel plug assay Aortas were isolated from male wild-type or RKTG-deleted littermates. The dissected aortic rings were embedded in Matrigel covered with DMEM containing VEGF, and incubated for 7 days. The rings were photographed and quantified using a 0-5 scale as described previously (Haas et al., 2006) . For Matrigel plug assay, Matrigel with or without VEGF was injected subcutaneously into the mid-ventral abdominal regions of male wild-type or RKTGdeleted mice. After 10 days, the mice were killed and the Matrigel plugs were removed and fixed, followed by immunohistochemistry.
